Inhibition of prostagrandin synthesis for the treatment of Duchenne musclar dystrophy

Inhibition of prostagrandin synthesis for the treatment of Duchenne musclar dystrophy - Inhibition of prostagrandin synthesis for the treatment of Duchenne musclar dystrophy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009307

Enrollment

Registered

2012-11-10

Start date

2012-11-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne muscular dystrophy

Interventions

oral adm,inistration of aspirin

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Duchenne muscular dystrophy Stage Ia-IVa Urine PGDM level is more than 4ng/mg Cr

Exclusion criteria

Exclusion criteria: Hypersensitivity to aspirin cases with gastric ulcer cases with hematological abnormality cases with beeding tendency Cases with heart, liver or kidney dysfunction Cases with chicken pox or influenza Cases administered beta-bloclker, ACE inhibitor, warfarin, steroid

Design outcomes

Primary

Measure	Time frame
Frequency and severity of adverse events	—

Secondary

Measure	Time frame
urine PGDM levels energy consumption the number of steps taken muscle/fat ration by MRI body weight serum CK levels motor function	—

Countries

Japan

Contacts

Public ContactYasuhiro Takeshima

Kobe University Graduate School of Medicine Department of Pediatrics

takesima@med.kobe-u.ac.jp078-382-6090

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026